Thèmes de la CIPIH
Charge de morbidité
L'identification des causes principales de morbidité et de mortalité dans les pays en développement et l'évaluation de leur coût humain, social et économique est une question importante. L'établissement des priorités de la recherche-développement et de l'innovation passe par la connaissance de la charge de morbidité pour les pays en développement et de la contribution possible des nouvelles technologies. Une autre question se pose, à savoir celle de l'adéquation des médicaments existants pour le traitement de certaines maladies.
Documents
-
10/90 Report on Health Research 2003-2004
-
Rapport sur la Santé dans le monde 2002 "Réduire les risques et promouvoir une vie saine"
-
The effect of the AIDS epidemic on economic welfare in sub-Saharan Africa | By D.T. Jamison, J.D. Sachs, J. Wang | CMH Working paper series, paper no. WG1:13 | 2001
-
Interventions to reduce tuberculosis mortality and transmission in low and middle income countries: effectiveness, cost-effectiveness and constraints to scaling up | By M.W. Borgdorff, K. Floyd, J.F. Broekmans | CMH Working paper series, paper no.WG6:8 | 2001
-
he evidence base for interventions to reduce under five mortality in low and middle income countries | By H. Gelband, S. Stansfield | CMH Working paper series, paper no.WG5:9 | 2001
-
Note on the health impact of water and sanitation services | By L. Vaz, P. Jha | CMH Working paper series, paper no.WG5:23 | 2001
-
The Global Burden of Chronic Diseases: Overcoming Impediments to Prevention and Control | By Derek Yach, Corinna Hawkes, C. Linn Gould, Karen J. Hofman | JAMA, June 2, 2004—Vol 291, No. 21 pp. 2616 -2622
-
Understanding the Burden of Disease: A Global Perspective | The Pfizer Journal, Global Edition Volume 1 No 1 | 2000
-
10/90 Report on Health Research 2003-2004 | Global Forum for Health Research | Geneva, 2004
-
Evidence-Based Global Health | P. Buekens, G. Keusch, J. Belizan, Z. A. Bhutta | JAMA Vol 291, 21, June 2004
-
Drug Development for Neglected Diseases: a Deficient Market and a Public Health Policy Failure | By P. Trouiller et al | The Lancet, vol. 359, pp.2188 – 94 | 2002
-
Working paper on priority infectious diseases requiring additional R&D | WHO- IFPMA Round Table | Geneva, 2001
-
Genomics and World Health | Report of the Advisory Committee on World Health | Geneva, 2002